Anupam Rasayan India Ltd has reported strong financial growth for the financial year ended March 31, 2026. The company announced an audited profit after tax of ₹1,613.96 million on a standalone basis and ₹2,221.99 million on a consolidated basis. Key highlights include a recommended final dividend of ₹1.50 per share and a significant move to acquire a 74.20% stake in Bliss GVS Pharma Limited, marking a major strategic expansion for the company.
FY26 Financial Performance
The company delivered robust financial results for the year ended March 31, 2026. On a consolidated basis, revenue from operations reached ₹23,654.55 million, reflecting substantial year-on-year growth. The profit after tax stood at ₹2,221.99 million. For the quarter ended March 31, 2026, the company posted a consolidated revenue of ₹6,357.83 million and a profit after tax of ₹559.96 million.
Strategic Acquisition and Funding
A pivotal outcome of the board meeting is the approval for the acquisition of a 74.20% controlling stake in Bliss GVS Pharma Limited. This acquisition is expected to significantly enhance the company’s market presence. Additionally, the board approved a private placement of 16,000 Secured, Rated, Unlisted, Redeemable, Non-Convertible Debentures (NCDs), aiming to raise ₹160 crore to support its strategic objectives.
Dividend and Governance Updates
In appreciation of the shareholders’ support, the board has recommended a final dividend of ₹1.50 per equity share, representing 15% of the face value of ₹10 per share. The distribution is subject to approval at the upcoming 23rd Annual General Meeting. In other corporate developments, the company announced the resignation of Mr. Vishal Thakkar from his position as Deputy Chief Financial Officer and Key Managerial Personnel, effective immediately.
Operational Highlights
The company remains focused on its core specialty chemicals business, leveraging its custom synthesis capabilities. Throughout FY26, Anupam Rasayan continued to integrate its international subsidiaries, including Jayhawk Fine Chemicals Corporation, contributing to its global scale. The company maintains a strong focus on maintaining effective internal financial controls and ensuring long-term value creation for stakeholders.
Source: BSE
